Gravity Rail raises $2.75M from Redesign Health for AI patient communication

Published

3 weeks ago

April 23, 2026

A startup that helps healthcare providers handle calls, texts and follow-ups with patients using AI has raised seed funding, Endpoints News learned exclusively.

Gravity Rail handles the process of communicating with patients, from enrollment and …

STAT+: Astellas treatment offers new hope to a devastated rare disease community

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

There’s fresh turmoil at the very top of the FDA: All weekend, questions have swirled over whether Commissioner Marty Makary will be ousted.

Also, we have a resurrected gene therapy effort in a once-devastated rare disease program, and underwhelming Alzheimer’s drug adoption.

Continue to STAT+ to read the full story…

Published

7 minutes ago

May 11, 2026

Temp User

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

There’s fresh turmoil at the very top of the FDA: All weekend, questions have swirled over whether Commissioner Marty Makary will be ousted.

Also, we have a resurrected gene therapy effort in a once-devastated rare disease program, and underwhelming Alzheimer’s drug adoption.

Continue to STAT+ to read the full story…

Braveheart Bio’s Hengrui-licensed cardiac drug scores second clinical win

Published

1 hour ago

May 11, 2026

Temp User

Braveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics recently scored a

Uncategorized

Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls

Published

2 hours ago

May 11, 2026

Temp User

While Daiichi Sankyo brought in $13.4 billion in 2025, setbacks forced the company to update its antibody-drug conjugate forecast, pushing demand below the minimum supply agreed upon with CMOs and prompting the cancellation of an in-house investment.